THIS PPT CONTAINS DESCRIPTION ABOUT HISTORY TAKING IN PATIENTS WITH CARDIORESPIRATORY DISEASES, EXPLAINED IN DETAILS ABOUT ALL SYMPTOMS & ITS DETAILED HISTORY.
Brief Presentation on clinical examination of Respiratory System with Report of Normal case
references:
macleod's clinical examination 13th edition
hutchinson clinical methods
R Alagappan - Manual of Practical Medicine, 4th Edition
Brief Presentation on clinical examination of Respiratory System with Report of Normal case
references:
macleod's clinical examination 13th edition
hutchinson clinical methods
R Alagappan - Manual of Practical Medicine, 4th Edition
Management of peripheral vascular disease by Sunil Kumar Dahasunil kumar daha
Please find the power point on Management of peripheral vascular disease . I tried to present it on understandable way and all the contents are reviewed by experts and from very reliable references. Thank you
Brief Presentation on clinical examination of Cardio Vascular System with Report of Normal case
references:
macleod's clinical examination 13th edition
hutchinson clinical methods
Management of peripheral vascular disease by Sunil Kumar Dahasunil kumar daha
Please find the power point on Management of peripheral vascular disease . I tried to present it on understandable way and all the contents are reviewed by experts and from very reliable references. Thank you
Brief Presentation on clinical examination of Cardio Vascular System with Report of Normal case
references:
macleod's clinical examination 13th edition
hutchinson clinical methods
Dyspnea derives from Greek for “ “ shortness of breath hard breathing ”. It is often also described as ”. This is a subjective sensation of breathing, from mild discomfort to feelings of suffocation. It is a sign of a variety of disorders and is primarily an indication of ventilation or of inadequate insufficient amounts of oxygen in the circulating blood .
Dyspnea happens when a “mismatch” occurs between afferent and efferent signaling. As the brain receives afferent ventilation information, it is able to compare it to the current level of respiration by the efferent signals. If the level of respiration is inappropriate for the body’s status and need, then dyspnea might occur
This ppt contains all the details about what is obesity, etiology, & mainly focuses on various methods of assessment of obesity from field tests to lab tests.
this ppt contains everything about evaluation in antenatal period by a physiotherapist for proper prescription of exercises. also it has details of contraindications & generalised guidelines for exercises in antenatal period.
this ppt is about therapeutic massage by physiotherapist. includes details like indications, contraindications, effects, preparation of patient & therapist & classification of manipulations.
this PPT contain detailed kinetics & kinematics of ankle joint & all joints of foot complex, muscles of ankle & foot complex, plantar arches & weight distribution during standing.
this PPT contains all the detailed information about walking aids including types, measurements, advantages & disadvantages, gait training with specific aid, etc.
This PPT contains a detailed explanation about resisted exercises, different types of exercise, indications & contraindications, manual & mechanical techniques.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
2. Demographic data
Chief complaint
History of present illness
Past medical history
Surgical history
Family history
Occupational history
Drug history
Social history
Personal history
3. Name – To address the patient
Age – To rule out age related disorders; anatomical &
physiological status of patient.
Gender – gender specific diseases
Address – for feasibility of patient to come to the
hospital for regular visits
Occupation – occupational hazards
Date of admission
Date of evaluation
Demographic data
4. Cough
Sputum production
breathlessness
Chest Pain
Hemoptysis
Wheeze / Stridor
Palpitations
[ MENTION THE DURATION OF EACH COMPLAINT ]
Chief complaints
5. History of present illness
Explain in detail about each & every symptom for
current episode
About investigations done
Admission to the hospital (if any)
HOPI
6. Cough
Reflex act of forceful expiration against a closed
glottis – generating positive intrathoracic pressure.
Aim is to clear the airways.
18. “Subjective experience of breathing discomfort that
consists of qualitatively distinct sensations that vary
in intensity. The experience derives from interactions
among multiple physiological, psychological, social,
and environmental factors that may induce secondary
physiological and behavioural responses.”
(The American Thoracic Society)
Dyspnea
21. Onset
Within minutes
Pneumothorax
Pulmonary embolism
Inhalation of foreign body
Larygeal edema
Left heart failure
Hours to Days
Acute Respiratory Distress Syndrome
Bronchial Asthma
Pneumonia
Left heart failure
22. Weeks to Months
COPD
ILD
Pleural effusion
Anemia
Thyrotoxicosis
Left ventricular failure
23. Grading of Dysponea (MMRC scale)
Grade Description of Breathlessness
0 I only get breathless with strenuous exercise.
1 I get short of breath when hurrying on level ground or walking up a slight
hill.
2 On level ground, I walk slower than people of the same age because of
breathlessness, or have to stop for breath when walking at my own pace.
3 I stop for breath after walking about 100 yards or after a few minutes on
level ground.
4 I am too breathless to leave the house or I am breathless when dressing.
24. GRADE DESCRIPTION
I No limitation to physical activity. Ordinary physical activity does not cause
undue dysponea, fatigue, palpitations or anginal pain.
II Slight limitation to physical activity. Comfortable at rest. Ordinary physical
activity results in dysponea, fatigue, palpitations or anginal pain.
III Marked limitation to physical activity. Comfortable at rest. Less than
ordinary physical activity causes dysponea, fatigue, palpitations or anginal
pain.
IV Symptoms at rest. Inability to carry out any physical activity without
discomfort. Symptoms of dysponea, fatigue, palpitations or anginal pain
may be present even at rest.
Grading of Dysponea (NYHA scale)
25. GRADE DEGREE DESCRIPTION
0 None Not troubled by shortness of breath on level or uphill
1 Mild Troubled by shortness of breath on level or uphill
2 Moderate Walks slower than person of same age
3 Severe Stops after walking 100yards
4 Very severe Breathlessness at rest
Grading of Dysponea (ATS scale)
30. Haemoptysis
Types
Frank- expectoration of blood only
Spurious- secondary to upper respiratory tract
infection above the level of larynx
Pseudo hemoptysis- due to pigment produced by
gram negative bacteria, Serratia marcescens
31. Severity
Mild <100ml /day
Moderate 100-150ml/day
Severe upto 200 ml/day
Massive > 600ml /day or 100ml/day for more than 3
days or 150 ml/hr.
32. HAEMOPTYSIS HAEMATEMESIS
Cough precedes Nausea & vomiting precedes
Frothy, may be mixed with sputum No air, mixed with food particles
pH alkaline pH acidic
Bright red Dark brown
H/o respiratory disease h/o peptic ulcer or chronic liver disease
Investigation: bronchoscopy Investigation: endoscopy
34. Stridor –
Characterised by prolonged inspiration through an
obstructed upper airways, which produces
characteristic sound.
Causes –
Laryngeal or tracheal obstruction
Laryngeal diphtheria
Mediastinal growth
Wheeze & stridor
35. Wheezing –
Characterised by prolonged expiration through an
obstructed lower airways, bronchi, bronchioles, etc.
This can also occur in cardiac & renal problems.
37. Physiological – exercise, emotional
Excessive intake of tea, coffee, tobacco, alcohol
consumption
Anxiety state
High output state – anemia, beriberi, thyrotoxicosis, A-V
fistula, etc.
Cardiac arrhythmias – heart block, atrial fibrilation,
extrasystole, paroxysmal tachycardia.
Drugs – sympathomimetics, nitrates, overdose of insulin or
digoxin
Miscellaneous – pheochromocytoma, hypoglycemia.
Palpitation
38. Any relevant same episodes in past
Medical history – if any
Surgical history – if any
Past history
39. Same disease to any other family members
Inherited diseses
Family history
40. Sleep
Appetite
Bowel
Bladder
Addictions –
Smoking (type of cigarettes, no. a day)
Tobacco chewing (type, how many times a day)
Alcohol intake (type, quantity per time, frequency)
Personal history
41. Type of work
Type of posture maintained
Hours of work per day
Travel for the job (hours/day)
Occupational history
42. Detailed home address
Environment surrounding house
Factories nearby house
Stairs to climb at home
Environmental history
43. How many members in family
Earning members of family
Color of ration card
Socioeconomic status